Combo therapy with Rituxan misses Phase III trial's goal

03/11/2009 | Bloomberg · American City Business Journals

A Phase III trial of Rituxan used in combination with other drugs for lupus nephritis failed to reduce symptoms after a year of treatment, co-developers Genentech and Biogen Idec said. A Biogen spokeswoman said the company is disappointed but not surprised by the results, adding that it will start looking for another potential medicine for lupus.

View Full Article in:

Bloomberg · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT